BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19225533)

  • 1. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
    Kastritis E; Zervas K; Symeonidis A; Terpos E; Delimbassi S; Anagnostopoulos N; Michali E; Zomas A; Katodritou E; Gika D; Pouli A; Christoulas D; Roussou M; Kartasis Z; Economopoulos T; Dimopoulos MA
    Leukemia; 2009 Jun; 23(6):1152-7. PubMed ID: 19225533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
    Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
    Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
    Krejci M; Scudla V; Tothova E; Schutzova M; Koza V; Adam Z; Krivanova A; Pour L; Buchler T; Sandecka V; Kralova D; Zahradova L; Vorlicek J; Mayer J; Hajek R
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):436-42. PubMed ID: 19951883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
    Avet-Loiseau H; Soulier J; Fermand JP; Yakoub-Agha I; Attal M; Hulin C; Garderet L; Belhadj K; Dorvaux V; Minvielle S; Moreau P;
    Leukemia; 2010 Mar; 24(3):623-8. PubMed ID: 20072152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Maintenance therapies of thalidomine and interferon-α in multiple myeloma].
    Li J; Cai JH; Huang BH; Liu JR; Zheng D
    Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(48):3417-20. PubMed ID: 22333255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].
    Chen SL; Qiu LG; Jiang B; Yu L; Zhong YP; Gao W
    Zhonghua Nei Ke Za Zhi; 2011 Apr; 50(4):291-4. PubMed ID: 21600146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang L; Ran X; Wang B; Sheng Z; Liu L
    Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
    Tan D; Kim K; Kim JS; Eom HS; Teoh G; Ong KH; Goh YT; Durie BG; Chng WJ; Lee JH
    Leuk Res; 2013 Sep; 37(9):1070-6. PubMed ID: 23816344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
    Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegård M; Forsberg K; Gruber A; Haglöf Kviele H; Johansson P; Lauri B; Mellqvist UH; Swedin A; Svensson M; Näsman P; Alici E; Gahrton G; Aschan J; Nahi H
    Br J Haematol; 2014 Mar; 164(5):684-93. PubMed ID: 24313224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
    Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
    Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of myeloma--state of the art.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
    Huang TC; Chen JH; Wu YY; Chang PY; Dai MS; Chao TY; Kao WY; Chen YC; Ho CL
    Ann Hematol; 2015 Jan; 94(1):107-15. PubMed ID: 25047657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.